Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Patients orientés vers l'Unité de Douleur Chronique pour un traitement palliatif par Ozonothérapie entre 2026 et 2029. (EPOOzo-2)

22 septembre 2026 mis à jour par: Bernardino Clavo, MD, PhD

Étude prospective et observationnelle des patients référés à l'Unité de Douleur Chronique pour un traitement palliatif par Ozonothérapie entre 2026 et 2029. Étude prospective EPOOzo-2.

The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms who have been referred to the Dr. Negrín University Hospital Chronic Pain Unit for adjuvant palliative treatment with ozone therapy between January 2026 and December 2029. Additionally, the study aims to evaluate several specific symptoms, hyperspectral and thermal images, non-invasive clinical parameters related to the Autonomic Nervous System (such as heart rate variability, electrochemical skin conductance, and vibration perception thresholds), oxidative stress and inflammatory parameters, and gut microbiota composition.

Aperçu de l'étude

Description détaillée

Patients are referred to the Chronic Pain Unit in the absence or failure of standard treatment, or when the standard treatment is associated with high morbidity or high risk. Frequently, these patients present alterations in self-perceived health-related quality of life (HRQoL), anxiety, depression, and other symptoms such as radiation-induced pelvic toxicity or chemotherapy-induced peripheral neuropathy (CIPN).

This prospective observational study (EPOOzo-2) aims to evaluate the effect of adjuvant symptomatic/palliative ozone therapy on HRQoL and potential changes from baseline. Specifically, it incorporates new non-invasive technologies to objectively assess microcirculation, neuropathy and autonomic regulation.

Main Objectives:

1. Analyze the impact on HRQoL of patients with refractory symptoms treated with ozone.

Secondary Objectives: Depending on the clinical case, analyze the impact of ozone treatment on: 2. Anxiety and depression. 3. Treated symptoms (e.g., pain, paresthesia). 4. Fatigue. 5. Toxicity grade (in cancer patients). 6. Non-invasive clinical parameters related to the Autonomic Nervous System (central and peripheral) and somatosensory function. 7. Biochemical parameters and gut microbiome analysis (in patients with systemic/rectal ozone).

Methodology: Prospective and observational study of patients referred for symptomatic/palliative ozone therapy between January 2026 and December 2029.

Assessments at weeks: 0 (baseline), 16 (end of O3/O2 treatment), 28 (12 weeks after the end of ozone), and 40 (24 weeks after the end of ozone).

Type d'étude

Observationnel

Inscription (Estimé)

120

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

  • Nom: Francisco Rodríguez-Esparragón, BSc, PhyD
  • Numéro de téléphone: +34 928449288
  • E-mail: afrodesp@gmail.com

Lieux d'étude

    • Las Palmas
      • Las Palmas de Gran Canaria, Las Palmas, Espagne, 35019
        • Recrutement
        • Dr. Negrín University Hospital
        • Contact:
          • Francisco Rodríguez-Esparragón, BSc, PhyD
          • Numéro de téléphone: +34 928449288
          • E-mail: afrodesp@gmail.com
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Patients submitted to the Chronic Pain Unit of the Hospital Universitario de Gran Canaria Dr. Negrín, between January 2026 and December 2029, for symptomatic/palliative treatment with ozone therapy because standard treatment does not exist, it has been unsuccessful, or it is associated with high risk or high morbidity.

La description

Inclusion Criteria:

  • 1. Adults ≥ 18 years old.
  • 2. Patients referred to the Chronic Pain Unit of the Dr. Negrín University Hospital for symptomatic/palliative treatment with ozone therapy because conventional treatment does not exist, has failed, has offered insufficient results, or is associated with high risk/morbidity.
  • 3. After evaluation of symptoms and patients, it exists a potential benefit of adding ozone treatment to the current treatment.
  • 4. Patients have no contraindications for ozone treatment.
  • 5. Patients must sign the specific Informed Consent for this study and for the ozone treatment.

Exclusion Criteria:

  • 1. Age < 18 years old.
  • 2. Psychiatric illness or social situations that would limit compliance with study requirements.

Contraindication or disability to attend scheduled treatments.

  • 3. Contraindication or disability to attend scheduled treatments.
  • 4. Uncontrolled clinical conditions (e.g., severe heart failure, massive hemorrhage, status epilepticus).
  • 5. Life expectancy < 6 months.
  • 6. Known allergy to ozone.
  • 7. Hemochromatosis (for systemic ozone treatment).
  • 8. Pregnancy (for systemic ozone treatment).
  • 9. Significant Glucose-6-Phosphate Dehydrogenase deficiency (Favism) (for systemic ozone treatment).
  • 10. Patients who do not meet the inclusion criteria.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: CASE_ONLY
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Ozone Group

Patients with refractory symptoms referred for palliative treatment with ozone therapy between 2026 and 2029.

Systemic (rectal, autohemotherapy) and/or local ozone administration (cutaneous, intravaginal, intravesical). Dosage, frequency, and duration will depend on the symptoms treated and clinical evolution. Usually planned 40 sessions over 4 months.

Autres noms:
  • Traitement à l'Ozone

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change from Baseline in Health-Related Quality of Life by the "EQ-5D-5L" Questionnaire (at the end of ozone therapy).
Délai: At the end of ozone therapy (approx. week 16).

Self-reported evaluation of 5 physical and emotional items scored in five levels, plus a Visual Analog Scale (EQ-VAS) from 0 (worst health) to 100 (best health).

At the end of ozone therapy (approx. week 16).

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change from Baseline in Health-Related Quality of Life by the "EQ-5D-5L" Questionnaire (at 12 weeks after the end of ozone therapy).
Délai: At 12 weeks after the end of ozone therapy (approx. week 28).

Self-reported evaluation of 5 physical and emotional items scored in five levels, plus a Visual Analog Scale (EQ-VAS) from 0 (worst health) to 100 (best health).

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Health-Related Quality of Life by the "EQ-5D-5L" Questionnaire (at 24 weeks after the end of ozone therapy).
Délai: At 24 weeks after the end of ozone therapy (approx. week 40).

Self-reported evaluation of 5 physical and emotional items scored in five levels, plus a Visual Analog Scale (EQ-VAS) from 0 (worst health) to 100 (best health).

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Anxiety and Depression Levels (HAD Scale) (at the end of ozone therapy).
Délai: At the end of ozone therapy (approx. week 16).

Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21 for each subscale, where higher scores indicate worse anxiety or depression.

At the end of ozone therapy (approx. week 16).
Change from Baseline in Anxiety and Depression Levels (HAD Scale) (at 12 weeks after the end of ozone therapy).
Délai: At 12 week after the end of ozone therapy (approx. week 28).

Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21 for each subscale, where higher scores indicate worse anxiety or depression.

At 12 week after the end of ozone therapy (approx. week 28).
Change from Baseline in Anxiety and Depression Levels (HAD Scale) (at 24 weeks after the end of ozone therapy).
Délai: At 24 week after the end of ozone therapy (approx. week 40).

Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21 for each subscale, where higher scores indicate worse anxiety or depression.

At 24 week after the end of ozone therapy (approx. week 40).
Change from Baseline in Health-Related Quality of Life by the "QLQ-C30" Questionnaire (only in cancer patients). (At the end of ozone therapy).
Délai: At the end of ozone therapy (approx. week 16).

The EORTC QLQ-C30 is a 30-item questionnaire that includes five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status scale, and several single items. Scores are transformed to a 0-100 scale. For functional and global health scales, higher scores represent better functioning or quality of life. For symptom scales/items, higher scores indicate greater symptomatology or problems

At the end of ozone therapy (approx. week 16).
Change from Baseline in Health-Related Quality of Life by the "QLQ-C30" Questionnaire (only in cancer patients). (At 12 weeks after the end of ozone therapy).
Délai: At 12 weeks after the end of ozone therapy (approx. week 28).

The EORTC QLQ-C30 is a 30-item questionnaire that includes five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status scale, and several single items. Scores are transformed to a 0-100 scale. For functional and global health scales, higher scores represent better functioning or quality of life. For symptom scales/items, higher scores indicate greater symptomatology or problems

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Health-Related Quality of Life by the "QLQ-C30" Questionnaire (only in cancer patients). (At 24 weeks after the end of ozone therapy).
Délai: At 24 weeks after the end of ozone therapy (approx. week 40).

The EORTC QLQ-C30 is a 30-item questionnaire that includes five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status scale, and several single items. Scores are transformed to a 0-100 scale. For functional and global health scales, higher scores represent better functioning or quality of life. For symptom scales/items, higher scores indicate greater symptomatology or problems

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Fatigue (Chalder Fatigue Scale and/or EORTC QLQ-FA12 for cancer patients) (at the end of ozone therapy).
Délai: At the end of ozone therapy (approx. week 16).

Assessed using the Chalder Fatigue Scale (CFQ-11) and/or EORTC QLQ-FA12 for cancer patients. Higher scores indicate greater fatigue

At the end of ozone therapy (approx. week 16).
Change from Baseline in Fatigue (Chalder Fatigue Scale and/or EORTC QLQ-FA12 for cancer patients) (at 12 weeks after the end of ozone therapy).
Délai: At 12 weeks after the end of ozone therapy (approx. week 28).

Assessed using the Chalder Fatigue Scale (CFQ-11) and/or EORTC QLQ-FA12 for cancer patients. Higher scores indicate greater fatigue

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Fatigue (Chalder Fatigue Scale and/or EORTC QLQ-FA12 for cancer patients) (at 24 weeks after the end of ozone therapy).
Délai: At 24 weeks after the end of ozone therapy (approx. week 40).

Assessed using the Chalder Fatigue Scale (CFQ-11) and/or EORTC QLQ-FA12 for cancer patients. Higher scores indicate greater fatigue

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Pain Score (Visual Analog Scale), (at the end of ozone therapy).
Délai: At the end of ozone therapy (approx. week 16).

Self-reported evaluation of pain severity using a Visual Analog Scale (VAS), scored from 0 ("No pain") to 10 ("Pain as bad as you can imagine").

At the end of ozone therapy (approx. week 16).
Change from Baseline in Pain Score (Visual Analog Scale), (at 12 weeks after the end of ozone therapy).
Délai: At 12 weeks after the end of ozone therapy (approx. week 28).

Self-reported evaluation of pain severity using a Visual Analog Scale (VAS), scored from 0 ("No pain") to 10 ("Pain as bad as you can imagine").

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Pain Score (Visual Analog Scale), (at 24 weeks after the end of ozone therapy).
Délai: At 24 weeks after the end of ozone therapy (approx. week 40).

Self-reported evaluation of pain severity using a Visual Analog Scale (VAS), scored from 0 ("No pain") to 10 ("Pain as bad as you can imagine").

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in the grade of toxicity secondary to cancer-treatment (if applicable) according to the CTCAE v5.0 scale, (at the end of ozone therapy).
Délai: At the end of ozone therapy (approx. week 16).

Grade of toxicity secondary to cancer-treatment according to the CTCAE v5.0 (Common Terminology Criteria for Adverse Events from the National Cancer Institute) scale. Each toxicity is usually scored from 0 (asymptomatic or mild symptoms) to 5 (death).

At the end of ozone therapy (approx. week 16).
Change from Baseline in the grade of toxicity secondary to cancer-treatment (if applicable) according to the CTCAE v5.0 scale, (at 12 weeks after the end of ozone therapy).
Délai: At 12 weeks after the end of ozone therapy (approx. week 28).

Grade of toxicity secondary to cancer-treatment according to the CTCAE v5.0 (Common Terminology Criteria for Adverse Events from the National Cancer Institute) scale. Each toxicity is usually scored from 0 (asymptomatic or mild symptoms) to 5 (death).

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in the grade of toxicity secondary to cancer-treatment (if applicable) according to the CTCAE v5.0 scale, (at 24 weeks after the end of ozone therapy).
Délai: At 24 weeks after the end of ozone therapy (approx. week 40).

Grade of toxicity secondary to cancer-treatment according to the CTCAE v5.0 (Common Terminology Criteria for Adverse Events from the National Cancer Institute) scale. Each toxicity is usually scored from 0 (asymptomatic or mild symptoms) to 5 (death).

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Electrochemical Skin Conductance (Sudoscan), (at the end of ozone therapy).
Délai: At the end of ozone therapy (approx. week 16).

Non-invasive evaluation of sudomotor function (small fiber neuropathy assessment). Measured in microsiemens (µS) on hands and feet using SUDOSCAN technology.

At the end of ozone therapy (approx. week 16).
Change from Baseline in Electrochemical Skin Conductance (Sudoscan), (at 12 weeks after the end of ozone therapy).
Délai: At 12 weeks after the end of ozone therapy (approx. week 28).

Non-invasive evaluation of sudomotor function (small fiber neuropathy assessment). Measured in microsiemens (µS) on hands and feet using SUDOSCAN technology.

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Vibration Perception Thresholds (Multifrequency Vibrometry), (at the end of ozone therapy).
Délai: At the end of ozone therapy (approx. week 16).

Assessment of large fiber nerve function using the VibroSense Meter II. Measures perception thresholds at different frequencies (e.g., 4Hz to 500Hz).

At the end of ozone therapy (approx. week 16).
Change from Baseline in Vibration Perception Thresholds (Multifrequency Vibrometry), (at 12 weeks after the end of ozone therapy).
Délai: At 12 weeks after the end of ozone therapy (approx. week 28).

Assessment of large fiber nerve function using the VibroSense Meter II. Measures perception thresholds at different frequencies (e.g., 4Hz to 500Hz).

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Postural Stability (Equilibrium Platform), (at the end of ozone therapy).
Délai: At the end of ozone therapy (approx. week 16).

Functional assessment of balance and Center of Pressure (CoP) displacement using specific force platforms.

At the end of ozone therapy (approx. week 16).
Change from Baseline in Postural Stability (Equilibrium Platform), (at 12 weeks after the end of ozone therapy).
Délai: At 12 weeks after the end of ozone therapy (approx. week 28).

Functional assessment of balance and Center of Pressure (CoP) displacement using specific force platforms.

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Heart Rate Variability (HRV), (at the end of ozone therapy).
Délai: At the end of ozone therapy (approx. week 16).

Non-invasive assessment of the Autonomic Nervous System (vagal tone) by analyzing time intervals between heartbeats (RR intervals).

At the end of ozone therapy (approx. week 16).
Change from Baseline in Heart Rate Variability (HRV), (at 12 weeks after the end of ozone therapy).
Délai: At 12 weeks after the end of ozone therapy (approx. week 28).

Non-invasive assessment of the Autonomic Nervous System (vagal tone) by analyzing time intervals between heartbeats (RR intervals).

At 12 weeks after the end of ozone therapy (approx. week 28).
Changes from baseline in Hyperspectral signatures and Infrared images obtained from hands and feet at the end of follow-up, (at the end of ozone therapy).
Délai: At the end of ozone therapy (approx. week 16).

Assessment of the percentage of reflectance for each wavelength of the hyperspectral and infrared images obtained with specific devices.

At the end of ozone therapy (approx. week 16).
Changes from baseline in Hyperspectral signatures and Infrared images obtained from hands and feet at the end of follow-up, (at 12 weeks after the end of ozone therapy).
Délai: At 12 weeks after the end of ozone therapy (approx. week 28).

Assessment of the percentage of reflectance for each wavelength of the hyperspectral and infrared images obtained with specific devices.

At 12 weeks after the end of ozone therapy (approx. week 28).
Changes from baseline in biochemical parameters of oxidative stress and inflammation (at the end of ozone therapy).
Délai: At the end of ozone therapy (approx. week 16).

Changes in serum levels of oxidative stress parameters (superoxide dismutase, glutathione, glutathione peroxidase, and free radicals) and proinflammatory cytokines.

At the end of ozone therapy (approx. week 16).
Changes from baseline in biochemical parameters of oxidative stress and inflammation (at 12 weeks after the end of ozone therapy).
Délai: At 12 weeks after the end of ozone therapy (approx. week 28).

Changes in serum levels of oxidative stress parameters (superoxide dismutase, glutathione, glutathione peroxidase, and free radicals) and proinflammatory cytokines.

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Gut Microbiota Composition (at the end of ozone therapy).
Délai: At the end of ozone therapy (approx. week 16).

Analysis of stool samples to evaluate changes in the intestinal microbiome (in patients treated with rectal ozone).

At the end of ozone therapy (approx. week 16).
Change from Baseline in Gut Microbiota Composition (at 12 weeks after the end of ozone therapy).
Délai: At 12 weeks after the end of ozone therapy (approx. week 28).

Analysis of stool samples to evaluate changes in the intestinal microbiome (in patients treated with rectal ozone).

At 12 weeks after the end of ozone therapy (approx. week 28).

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chaise d'étude: Bernardino Clavo, MD, PhD, Dr. Negrín University Hospital, Las Palmas, Spain
  • Chercheur principal: Francisco Rodríguez-Esparragón, BSc, PhyD, Dr. Negrín University Hospital, Las Palmas, Spain
  • Chercheur principal: Ángeles Cánovas-Molina, RN, Dr. Negrín University Hospital, Las Palmas, Spain

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

14 janvier 2026

Achèvement primaire (Estimé)

31 décembre 2029

Achèvement de l'étude (Estimé)

30 juin 2030

Dates d'inscription aux études

Première soumission

23 décembre 2025

Première soumission répondant aux critères de contrôle qualité

23 décembre 2025

Première publication (Réel)

8 janvier 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

23 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

22 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

  • It will be available (after request): Individual participant data (IPD) that underlie the results reported in further articles, after deidentification
  • Data will be available after publication, ending 36 months following the article publication.
  • They will be available for investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose

Délai de partage IPD

Data will be available after publication, ending 36 months following article publication.

Critères d'accès au partage IPD

They will be available for investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • CIF

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner